QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
NASDAQ:SPRB

Spruce Biosciences Stock Forecast, Price & News

$2.57
-0.01 (-0.39%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.25
$2.58
50-Day Range
$2.33
$5.03
52-Week Range
$2.25
$28.49
Volume
440,374 shs
Average Volume
1.20 million shs
Market Capitalization
$60.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.55
30 days | 90 days | 365 days | Advanced Chart
Receive SPRB News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Spruce Biosciences logo

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRB
Phone
N/A
Fax
N/A
Employees
17
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$6.44 per share

Profitability

Net Income
$-29.54 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,328,000
Market Cap
$60.30 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/24/2022
Next Earnings (Estimated)
3/28/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

339th out of 1,415 stocks

Pharmaceutical Preparations Industry

155th out of 683 stocks

Analyst Opinion: 4.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Spruce Biosciences (NASDAQ:SPRB) Frequently Asked Questions

Is Spruce Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Spruce Biosciences stock.
View analyst ratings for Spruce Biosciences
or view top-rated stocks.

Are investors shorting Spruce Biosciences?

Spruce Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 1,210,000 shares, an increase of 78.7% from the December 15th total of 677,300 shares. Based on an average trading volume of 3,720,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 17.1% of the company's stock are short sold.
View Spruce Biosciences' Short Interest
.

When is Spruce Biosciences' next earnings date?

Spruce Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
View our earnings forecast for Spruce Biosciences
.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) announced its earnings results on Monday, November, 15th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08.
View Spruce Biosciences' earnings history
.

What price target have analysts set for SPRB?

6 brokers have issued twelve-month price objectives for Spruce Biosciences' stock. Their forecasts range from $5.00 to $20.00. On average, they anticipate Spruce Biosciences' stock price to reach $10.60 in the next twelve months. This suggests a possible upside of 312.5% from the stock's current price.
View analysts' price targets for Spruce Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Spruce Biosciences' key executives?

Spruce Biosciences' management team includes the following people:
  • Mr. Michael G. Grey, Exec. Chairman (Age 68, Pay $14.85k)
  • Mr. Richard A. King M.B.A., CEO & Director (Age 56, Pay $839.55k)
  • Mr. Samir M. Gharib CPA, M.B.A., CPA, Chief Financial Officer (Age 39, Pay $454.9k)
  • Dr. Rosh Dias, Chief Medical Officer (Age 53, Pay $623.44k)

When did Spruce Biosciences IPO?

(SPRB) raised $75 million in an IPO on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

What is Spruce Biosciences' stock symbol?

Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."

Who are Spruce Biosciences' major shareholders?

Spruce Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.17%). Company insiders that own Spruce Biosciences stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest.
View institutional ownership trends for Spruce Biosciences
.

Which major investors are buying Spruce Biosciences stock?

SPRB stock was bought by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC. Company insiders that have bought Spruce Biosciences stock in the last two years include Bali Muralidhar, and Venture Fund Iii L Rivervest.
View insider buying and selling activity for Spruce Biosciences
or or view top insider-buying stocks.

How do I buy shares of Spruce Biosciences?

Shares of SPRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spruce Biosciences' stock price today?

One share of SPRB stock can currently be purchased for approximately $2.57.

How much money does Spruce Biosciences make?

Spruce Biosciences has a market capitalization of $60.30 million. The company earns $-29.54 million in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Spruce Biosciences have?

Spruce Biosciences employs 17 workers across the globe.

What is Spruce Biosciences' official website?

The official website for Spruce Biosciences is www.sprucebiosciences.com.

How can I contact Spruce Biosciences?

The company can be reached via email at [email protected].


This page was last updated on 1/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.